[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 6, 2010

Hormonal Therapy for Prostate Cancer in Men With Heart Disease

JAMA. 2010;303(1):32-33. doi:10.1001/jama.2009.1931

To the Editor: In the study by Dr Nanda and colleagues,1 although the adjusted hazard ratio for all-cause mortality with neoadjuvant androgen deprivation therapy (ADT) was less than 1.0 in men without comorbidities, the absolute death rate was higher in men who received neoadjuvant ADT (9.6%) than in men who did not (6.7%). Although the authors state that this can be explained by the more unfavorable prostate cancer prognostic factors for the neoadjuvant ADT group, the possibility that ADT promoted castration-refractory disease and all-cause mortality cannot be ruled out.

First Page Preview View Large
First page PDF preview
First page PDF preview
×